Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer
British Journal of Cancer 116, 1312 (9 May 2017). doi:10.1038/bjc.2017.91
Authors: A Janssen, C P M Verkleij, A van der Vlist, R H J Mathijssen, H J Bloemendal & R ter Heine
http://ift.tt/2o2mTD5
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου